Expression of p16, ERCC1, and EGFR amplification as predictors of responsiveness of locally advanced squamous cell carcinomas of head and neck (SCCHN) to cisplatin, radiotherapy, and erlotinib: A phase II randomized trial.
Melissa Austin
No relevant relationships to disclose
Rodney Schmidt
No relevant relationships to disclose
Upendra Parvathaneni
No relevant relationships to disclose
Julie E. Bauman
Research Funding - Roche/Genentech
David N. Hayes
No relevant relationships to disclose
Michael A. Papagikos
No relevant relationships to disclose
Keith D. Eaton
No relevant relationships to disclose
Jay Justin Liao
No relevant relationships to disclose
Eduardo Mendez
No relevant relationships to disclose
Brenda F Kurland
No relevant relationships to disclose
Shawn Xiaoyu
No relevant relationships to disclose
Sarah G. Wallace
No relevant relationships to disclose
Renato Martins
Honoraria - OSI Pharmaceuticals; Roche/Genentech
Research Funding - OSI Pharmaceuticals; Roche/Genentech